Patient Investors Win with 4,000% 5,000% Over Five Years
Long-term holders in NVDA, AMD, and LLY are posting outsized gains as AI and GLP-1 drug momentum persists. Traders wh...
GLP-1 Drugs
GLP-1 Drugs tag page compiles 4 articles on how obesity drugs impact costs, shares, and budgeting. Find practical insights to safeguard your finances as pharmaceutical trends shape prices and plans.
10 articles
This News From Novo: A Warning for Eli Lilly Shareholders
A GLP-1 drug race is moving from injections to pills, reshaping the landscape for Novo Nordisk and Eli Lilly. Here’s ...
Lilly Just Announced Fantastic News for Shareholders
Eli Lilly is delivering big news for investors. The rallying force behind recent gains comes from GLP-1 drugs, manufa...
Lilly Stock Heading $1,000? What Investors Should Know
Investors are watching Eli Lilly as GLP-1 drugs like Mounjaro and Zepbound power growth. This article breaks down the...
This Promising GLP-1 Drug Could Renew Novo Nordisk Hope
Novo Nordisk has faced headwinds, but a new GLP-1 drug could change the game. This article breaks down what investors...
Hims Hers Really Growth Stock Faces Reality Check Now
Hims & Hers Health shifts to selling branded Wegovy and Ozempic after a settlement with Novo Nordisk, reversing regul...
Hims Hers Health Shares Rally on Novo Nordisk Deal
Hims Hers Health shares jumped after news of a Novo Nordisk collaboration. This guide breaks down what the deal could...
GLP-1s Cure Hunger More, Study Finds Broad Impact
A sweeping real-world study of roughly 600,000 GLP-1 users finds cravings for cigarettes, alcohol, and other addictio...
Hims Hers Snaps Losing Streak as EPS Beat Fails Again
Hims & Hers beat quarterly EPS but trimmed full-year guidance, extending a slide in its stock as regulatory headwinds...
Forget Ozempic: This Obesity-Drug Giant Grabs GLP-1 Gold
As GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...